SG11202008921YA - Micro-rna and obesity - Google Patents
Micro-rna and obesityInfo
- Publication number
- SG11202008921YA SG11202008921YA SG11202008921YA SG11202008921YA SG11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA
- Authority
- SG
- Singapore
- Prior art keywords
- obesity
- rna
- micro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862642934P | 2018-03-14 | 2018-03-14 | |
PCT/US2019/022350 WO2019178410A1 (en) | 2018-03-14 | 2019-03-14 | Micro-rna and obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008921YA true SG11202008921YA (en) | 2020-10-29 |
Family
ID=67908026
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008921YA SG11202008921YA (en) | 2018-03-14 | 2019-03-14 | Micro-rna and obesity |
SG11202008925VA SG11202008925VA (en) | 2018-03-14 | 2019-03-14 | Inhibitors of micro-rna 22 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008925VA SG11202008925VA (en) | 2018-03-14 | 2019-03-14 | Inhibitors of micro-rna 22 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11499152B2 (en) |
EP (2) | EP3765619A4 (en) |
JP (2) | JP2021518841A (en) |
KR (2) | KR20200132920A (en) |
CN (2) | CN112119159A (en) |
AU (2) | AU2019234916A1 (en) |
BR (2) | BR112020018705A2 (en) |
CA (2) | CA3093572A1 (en) |
RU (2) | RU2020132725A (en) |
SG (2) | SG11202008921YA (en) |
WO (2) | WO2019178410A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020018705A2 (en) | 2018-03-14 | 2021-01-05 | Beth Israel Deaconess Medical Center | MICROWAVE INHIBITORS 22 |
CN110609142A (en) * | 2019-10-09 | 2019-12-24 | 广州医科大学附属第二医院 | Method for detecting binding capacity of peripheral blood FTO protein and self-regulation element and application |
CN115029347B (en) * | 2022-05-11 | 2024-02-20 | 珠海中科先进技术研究院有限公司 | Molecular monitoring sequence for recognizing and regulating hepatic and renal cell fibrosis, recombinant plasmid and virus inhibition |
EP4353823A1 (en) * | 2022-10-12 | 2024-04-17 | Resalis Therapeutics S.r.l. | Inhibitors of micro-rna 22 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
AU731909B2 (en) | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
SK17432000A3 (en) | 1998-05-26 | 2001-07-10 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
JP4868739B2 (en) | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Nucleic acid delivery methods |
DK2302055T3 (en) * | 2004-11-12 | 2014-10-13 | Asuragen Inc | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
JP2009519339A (en) * | 2005-12-12 | 2009-05-14 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | MicroRNAs that regulate myocyte proliferation and differentiation |
AU2013254923A1 (en) * | 2006-04-03 | 2013-11-28 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide |
DK2666859T3 (en) | 2006-04-03 | 2019-04-08 | Roche Innovation Ct Copenhagen As | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES |
ES2463665T3 (en) * | 2007-10-04 | 2014-05-28 | Stella Aps | Combination treatment for the treatment of hepatitis C virus infection |
WO2010120803A2 (en) * | 2009-04-13 | 2010-10-21 | Somagenics Inc. | Methods and compositions for detection of small rnas |
NZ597078A (en) * | 2009-06-08 | 2013-11-29 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
UY33807A (en) * | 2010-12-17 | 2012-07-31 | Sanofi Sa | miRNAs as indicators of tissue status or of diseases such as osteoarthritis |
CA2832899A1 (en) | 2011-04-12 | 2012-10-18 | Beth Israel Deaconess Medical Center, Inc. | Micro-rna inhibitors and their uses in disease |
WO2013125691A1 (en) * | 2012-02-23 | 2013-08-29 | 住友ベークライト株式会社 | Method for classifying test body fluid sample |
US9034839B2 (en) | 2012-04-20 | 2015-05-19 | Aptamir Therapeutics, Inc. | miRNA modulators of thermogenesis |
WO2013181613A1 (en) * | 2012-05-31 | 2013-12-05 | Research Development Foundation | Mirna for the diagnosis and treatment of autoimmune and inflammatory disease |
WO2013192576A2 (en) * | 2012-06-21 | 2013-12-27 | Miragen Therapeutics | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
US9822358B2 (en) * | 2013-10-18 | 2017-11-21 | Beth Israel Deaconess Medical Center | Treatment of cancers with micro-RNA inhibitors |
CA2935426C (en) * | 2014-01-30 | 2023-07-25 | F. Hoffmann-La Roche Ag | Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target |
US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
US20180042847A1 (en) * | 2015-03-16 | 2018-02-15 | Duncan ROSS | Method of treatment comprising membrane-enclosed vesicle |
WO2017187426A1 (en) * | 2016-04-29 | 2017-11-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
CN107432933A (en) * | 2017-07-13 | 2017-12-05 | 中南大学湘雅三医院 | Applications of the miR 22 as target site in the chemotherapy sensitizing medicine for preparing carcinoma of urinary bladder |
WO2019053235A1 (en) * | 2017-09-15 | 2019-03-21 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
BR112020018705A2 (en) | 2018-03-14 | 2021-01-05 | Beth Israel Deaconess Medical Center | MICROWAVE INHIBITORS 22 |
WO2019217907A1 (en) * | 2018-05-11 | 2019-11-14 | The Regents Of The University Of California | Methods and compositions for the treatment of hepatic and metabolic diseases |
-
2019
- 2019-03-14 BR BR112020018705-4A patent/BR112020018705A2/en not_active Application Discontinuation
- 2019-03-14 BR BR112020018752-6A patent/BR112020018752A2/en not_active Application Discontinuation
- 2019-03-14 AU AU2019234916A patent/AU2019234916A1/en active Pending
- 2019-03-14 KR KR1020207029243A patent/KR20200132920A/en unknown
- 2019-03-14 JP JP2020549635A patent/JP2021518841A/en active Pending
- 2019-03-14 US US16/979,782 patent/US11499152B2/en active Active
- 2019-03-14 EP EP19768368.3A patent/EP3765619A4/en active Pending
- 2019-03-14 CA CA3093572A patent/CA3093572A1/en active Pending
- 2019-03-14 KR KR1020207029242A patent/KR20200131287A/en unknown
- 2019-03-14 CN CN201980032204.4A patent/CN112119159A/en active Pending
- 2019-03-14 CN CN201980018587.XA patent/CN111918968B/en active Active
- 2019-03-14 CA CA3093844A patent/CA3093844A1/en active Pending
- 2019-03-14 US US16/979,777 patent/US11753639B2/en active Active
- 2019-03-14 SG SG11202008921YA patent/SG11202008921YA/en unknown
- 2019-03-14 WO PCT/US2019/022350 patent/WO2019178410A1/en unknown
- 2019-03-14 WO PCT/US2019/022351 patent/WO2019178411A1/en active Search and Examination
- 2019-03-14 EP EP19768285.9A patent/EP3765610A4/en active Pending
- 2019-03-14 JP JP2020573079A patent/JP7318166B2/en active Active
- 2019-03-14 SG SG11202008925VA patent/SG11202008925VA/en unknown
- 2019-03-14 AU AU2019234917A patent/AU2019234917A1/en active Pending
- 2019-03-14 RU RU2020132725A patent/RU2020132725A/en unknown
- 2019-03-14 RU RU2020131372A patent/RU2020131372A/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2020131372A (en) | 2022-04-14 |
CA3093572A1 (en) | 2019-09-19 |
US20210017520A1 (en) | 2021-01-21 |
JP2021518841A (en) | 2021-08-05 |
US20210017521A1 (en) | 2021-01-21 |
CN111918968B (en) | 2023-11-24 |
EP3765610A4 (en) | 2022-01-19 |
AU2019234917A1 (en) | 2020-10-01 |
CN112119159A (en) | 2020-12-22 |
BR112020018752A2 (en) | 2021-01-05 |
CA3093844A1 (en) | 2019-09-19 |
KR20200132920A (en) | 2020-11-25 |
EP3765619A4 (en) | 2021-12-08 |
JP7318166B2 (en) | 2023-08-01 |
US11753639B2 (en) | 2023-09-12 |
JP2021518159A (en) | 2021-08-02 |
SG11202008925VA (en) | 2020-10-29 |
RU2020132725A (en) | 2022-04-15 |
WO2019178410A1 (en) | 2019-09-19 |
KR20200131287A (en) | 2020-11-23 |
EP3765619A1 (en) | 2021-01-20 |
US11499152B2 (en) | 2022-11-15 |
BR112020018705A2 (en) | 2021-01-05 |
EP3765610A1 (en) | 2021-01-20 |
AU2019234916A1 (en) | 2020-10-15 |
CN111918968A (en) | 2020-11-10 |
WO2019178411A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275737A (en) | Antibodies and variants thereof against tigit | |
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
EP4076448A4 (en) | Fluoroalkyl-oxadiazoles and uses thereof | |
SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
SG11202008921YA (en) | Micro-rna and obesity | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
IL278832A (en) | Optimized gp41-binding molecules and uses thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
IL276807A (en) | Modified plyss2 lysins and uses thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof | |
IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
GB201812561D0 (en) | Biomarkers and uses thereof | |
IL283890A (en) | Anti-periostin antibodies and uses thereof | |
GB201806042D0 (en) | Biomarkers and uses thereof | |
IL275211A (en) | Fast and partition-resilient blockchains | |
SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
IL280369A (en) | New myokines and uses thereof |